CBD, or cannabidiol, is one of over 144 cannabinoids derived from hemp—a plant with a long history of cultivation in Europe. Unlike THC, it produces no psychoactive effects, meaning it doesn't alter consciousness or perception. Sourced from European industrial hemp, CBD is the subject of growing global research. As experts in cannabinoid science, we've reviewed the most credible studies on its potential benefits.
The World Health Organization (WHO) recognizes CBD as non-toxic. In France, it's available by prescription for conditions like multiple sclerosis and epilepsy. A June 2018 update from the MILDECA website restricts industrial hemp use to:
A comprehensive Le Monde investigation reveals therapeutic cannabis is accessible to 18% of the world's population—1.4 billion people in 37 countries. Globally, 31 countries have decriminalized or legalized it, with 24 for therapeutic use. In Europe, progress is notable: from zero in 1966 to 19 countries today, including 12 legalizing therapeutic use and 7 decriminalizing recreational.
CBD interacts with the endocannabinoid system, a network of receptors throughout the body that maintains homeostasis—regulating temperature, pH, minerals, and more.
Research from the University of Bologna's Department of Internal Medicine (2008) and the University of Connecticut's School of Medicine (2017) demonstrates CBD restores bodily balance, including temperature, acidity, and blood sugar levels.
A 2019 multinational study by neurobiologists from Canada, the US, and Italy found CBD boosts serotonin production—the "happiness hormone"—modulating mood, sleep, and stress while reducing anxiety and neuropathic pain.
Another 2019 Nature study showed cannabis, including CBD, effectively managed pain post-spinal cord injury in 8 participants unresponsive to prior treatments.
Compared to epilepsy and psychiatric drugs, CBD offers more tolerable side effects like fatigue, diarrhea, or appetite changes, per a 2017 Nova Institute analysis. It serves as effective adjunctive therapy.
A 2020 University of Melbourne study echoed this, noting high tolerance despite occasional headaches (17%).
The American College of Neuropsychopharmacology's 2011 Nature-published trial confirmed CBD reduces public speaking-induced anxiety in social phobia cases, outperforming placebo.
A 2016 study from the University of Cantabria and Barcelona's Institute of Biomedicine highlighted CBD's rapid antidepressant effects.
Pharmacologist Yasmin Hurd's 2019 research showed CBD aids opioid addiction relief without significant side effects.
In summary, rigorous studies affirm CBD's potential for pain relief, anxiety reduction, mood support, and more—with minimal side effects. Ongoing research promises further insights.
Related articles:
The list of countries in the world where CBD is legal. What about France?
Cannabis compound found to be effective in fighting antibiotic resistance
Therapeutic cannabis: the National Assembly validates a two-year test in France!
